Synonyms for dyspareunia or Related words with dyspareunia

vaginismus              adenomyosis              anorgasmia              vulvodynia              impotence              noncoital              metrorrhagia              proctalgia              hypermenorrhea              vestibulodynia              dermatopathy              otalgia              dysuria              vestibulitis              gravidarum              prostatism              leucorrhea              anismus              polymenorrhea              prostatomegaly              orgasmic              mittelschmerz              vaginitis              hyperemesis              fsad              adenomyomas              frigidity              gynecomastia              mastodynia              dysmenorrhea              menorrhagia              varicocele              dysmenorrheal              kraurosis              dyschexia              premenstural              leukorrhea              hsdd              spermatorrhea              glossodynia              abacterial              vulvovaginal              dyssynergia              premenstrual              vaginism              aurium              vulvae              oligomenorrhea              prostatodynia              prostatis             

Examples of "dyspareunia"
Dyspareunia is a complex problem and frequently has a multifactorial cause. A new way has been recently suggested to define dyspareunia by dissecting it into primary, secondary, and tertiary sources of pain.
Dyspareunia (from Greek, δυσ-, "dys-" "bad" and πάρευνος, "pareunos" "bedfellow", meaning "badly mated"). The previous "Diagnostic and Statistical Manual of Mental Disorders", the "DSM-IV", stated that the diagnosis of dyspareunia is made when the patient complains of recurrent or persistent genital pain before, during, or after sexual intercourse that is not caused exclusively by lack of lubrication or by vaginal spasm (vaginismus). After the text revision of the fourth edition of the DSM, a debate arose, with arguments to recategorize dyspareunia as a pain disorder instead of a sex disorder, with Charles Allen Moser, a physician, arguing for the removal of dyspareunia from the manual altogether. The most recent version, the DSM 5 has grouped dyspareunia under the diagnosis of Genito-Pelvic Pain/Penetration Disorder.
Globally, dyspareunia has been estimated to affect between 8–21% of women, at some point in their lives.
Yitzchak M. "Irv" Binik (born February 6, 1949) is an American-Canadian psychologist whose main research interest is human sexuality, specifically sexual pain (vaginismus and dyspareunia).
The signs and symptoms are similar to other cervical cancers and may include post-coital bleeding and/or pain during intercourse (dyspareunia). Early lesions may be completely asymptomatic.
Chronic pelvic pain is a common condition with rate of dysmenorrhoea between 16.8—81%, dyspareunia between 8—21.8%, and noncyclical pain between 2.1—24%.
It usually does not pose any medical problems, though it can be associated with dyspareunia (pain during sexual intercourse) and dysmenorrhea (pain during menstruation).
Vaginal hypoplasia, a relatively frequent finding in CAIS and some forms of PAIS, is associated with sexual difficulties including vaginal penetration difficulties and dyspareunia.
The signs and symptoms are similar to other cervical cancers and may include post-coital bleeding and/or pain during intercourse (dyspareunia). Early lesions may be completely asymptomatic.
Vaginal hypoplasia, a relatively frequent finding in CAIS and some forms of PAIS, is associated with sexual difficulties including vaginal penetration difficulties and dyspareunia.
Low levels of estrogen can lead to dyspareunia and limited genital arousal because of changes in the four layers of the vaginal wall.
Ospemifene (commercial name Osphena produced by Shionogi) is an oral medication indicated for the treatment of dyspareuniapain during sexual intercourseencountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM) acting similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by "vulval and vaginal atrophy."
Perineoplasty is generally considered effective for treatment of dyspareunia, including that caused by lichen sclerosus, and vaginismus. It is also considered an effective treatment for vulvar vestibulitis, although it is generally recommended following the failure of nonsurgical methods.
Sexual pain disorders affect women almost exclusively and are also known as dyspareunia (painful intercourse) or vaginismus (an involuntary spasm of the muscles of the vaginal wall that interferes with intercourse).
The person with a longitudinal vaginal septum may be asymptomatic and not aware of the condition. If dyspareunia is a problem a simple resection of the septum could be performed.
Residual ovary syndrome or ovarian remnant syndrome is a condition that occurs when ovarian tissue is left behind following oophorectomy, causing development of a pelvic mass, pelvic pain, and occasionally dyspareunia. The frequency is about 1.8% in spayed female dogs.
In women with SS, vaginal dryness, vulvodynia and dyspareunia (painful sexual intercourse) are often reported; personal lubricants are recommended to help lessen irritation or pain that may result from dryness in the vaginal and vulva areas.
Side effects that are shared among most different types of pessaries are risks of increased vaginal discharge, vaginal irritation, ulceration, bleeding, and dyspareunia (painful intercourse for the male or female).
Sexual disorders and gender dysphoria may be diagnosed, including dyspareunia and ego-dystonic homosexuality. Various kinds of paraphilia are considered mental disorders (sexual arousal to objects, situations, or individuals that are considered abnormal or harmful to the person or others).
Two 12-week phase 3 clinical trials were performed for ospemifene. One evaluated the effects of Ospemifene on vaginal tissue thickness, composition and vaginal pH. The other evaluated the effects of Ospemifene on vaginal tissue and on symptoms of dyspareunia. Between the two trials, 4 signs and symptoms were measured. These included three tissue-related signs, two of which represented histological changes in the vaginal tissue (change in percent parabasal cells and change in percent superficial cells) and the third was "change in vaginal pH". Dyspareunia was evaluated in one of the trials. It was defined as "change in most bothersome symptom" of discomfort during sexual activity and further limited to symptoms of either vaginal dryness or vaginal pain." Ospemifene produced more changes in vaginal tissue and greater reduction in dyspareunia symptoms than placebo. A dose-response also was observed in the trial; ospemifene 60 mg had greater efficacy than ospemifene 30 mg. Safety was also evaluated in these phase 3 trials. There was a 5.2% increase in the incidence of hot flushes, 1.6% increase in urinary tract infections, and 0.5% increase in the incidence of headache with ospemifene over placebo. One of the phase 3 trials was a randomized, double-blind placebo-controlled trial in 826 post-menopausal women. The trial patients were required to have one or more symptom of vulvovaginal atrophy (VVA) that was moderate or severe in nature with fewer than 5% of cells that were superficial when examined by a vaginal smear and a vaginal pH of at least 5.0. This trial did not quantify relief of dyspareunia as a study outcome measure. The other phase 3 trial was conducted in 605 women aged 40 to 80, who were diagnosed with VVA, and whose worst symptom was dyspareunia.